Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.8K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

3.8K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

80
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
80
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An activatable naphthalimide-based fluorescent probe for hydrogen peroxide detection: visualizing microcystin-LR induced oxidative stress in zebrafish and hepatocyte injury mechanism.

The Analyst·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression.

Cancer letters·2026
Same author

VEGFA-Targeted M3-F4 Ionizable Lipid Nanoparticles Improve Diabetic Retinopathy.

Molecular pharmaceutics·2026
Same author

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.

European urology·2026
Same author

Time-dependent diffusion MRI as in vivo histology: microstructural biomarkers for breast cancer diagnosis and prognostic stratification.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026

相关实验视频

Updated: Jun 4, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

一个I期剂量确定设计,包括患者内剂量升级.

Beibei Guo1, Suyu Liu2

  • 1Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA.

Pharmaceutical statistics
|December 26, 2024
PubMed
概括

本研究为I期试验引入了患者内剂量升级持续重新评估方法 (IP-CRM). IP-CRM设计有效地识别了最大耐受剂量 (MTD),采用较小的样本大小,改进了传统方法.

科学领域:

  • 临床试验方法论 临床试验方法论
  • 生物统计学 生物统计学
  • 药学指标 (Pharmacometrics) 是一个指标.

背景情况:

  • 传统的I期试验需要大量的患者队伍来确定最大耐受剂量 (MTD).
  • 在儿科或罕见癌症试验中,招募足够多的患者参加剂量确定研究是具有挑战性的.
  • 现有的设计可能无法有效利用患者数据来确定MTD.

研究的目的:

  • 提出一种新的I期剂量检测设计,IP-CRM,将患者内剂量升级与持续再评估方法 (CRM) 整合起来.
  • 在I期临床试验中提高MTD识别的效率和准确性.
  • 解决患者招募和数据利用中传统设计的局限性.

主要方法:

  • 拟议的IP-CRM设计允许基于个体毒性和累积数据的患者内剂量升级.
  • 适应性更新患者队列的起始剂量.
  • 扩展IP-CRM以考虑延续效应和患者内相关性.

主要成果:

  • 与标准I阶段设计相比,IP-CRM设计显著降低了样本大小要求.
  • 模拟研究表明,在识别MTD时,效率提高.
  • 与标准CRM和3+3设计相比,IP-CRM显示了正确识别MTD的增强概率.
关键词:
这就是为什么CRM是CRMCRM.第一个阶段I阶段转载过来的时间.发现剂量发现剂量在患者内治疗.

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K

相关实验视频

Last Updated: Jun 4, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K

结论:

  • IP-CRM设计为I阶段剂量检测研究提供了更有效的方法.
  • 这种新的设计对于具有有限患者人群的试验尤其有益.
  • 在早期瘤学试验中,IP-CRM提高了MTD识别精度和样本大小效率.